For how we live.
AMPLIFIED enriched for early rheumatoid arthritis patients thought to respond best to abatacept, then compared it head-to-head with adalimumab. At week 24 the two drugs were indistinguishable.
Three 2025 reviews of the same drugs reach three answers: a matched cohort finds less cardiovascular disease on biologics, a network meta-analysis flags one drug as raising events, and 43 trials find nothing.
In the COSPIRIT-JIA trial, most children with two stubborn forms of juvenile idiopathic arthritis responded to ixekizumab by week 16 — but the main result had no control group.